Acasti Pharma: Another Fish Oil Derived Product Nearing The Market [Seeking Alpha]
Acasti Pharma, Inc. (ACST)
Last acasti pharma, inc. earnings: 2/14 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acastipharma.com/investors
Company Research
Source: Seeking Alpha
Acasti Pharma: Another Fish Oil Derived Product Nearing The Market Acasti Pharma Inc. ( ACST AMRN Acasti’s current trial situation and catalysts Top-line data from the two ongoing phase 3 trials is expected by December 2019 and January 2020, respectively. Full data readout will be in March 2020. If phase 3 readout is successful, the company expects to file NDA mid-2020. The company recently completed 100% patient randomization in its ongoing TRILOGY 1 and TRILOGY 2 phase 3 trial programs of CaPre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG). The phase 3, multi-center, multi-national, placebo-controlled, randomized, double-blind trial programs will assess the safety and efficacy of CaPre 4 g daily dosage in patients with severe HTG. Primary outcome is the percent change in fasting triglyceride (TG) levels from baseline, in patients with fasting TG levels =500 mg/dL and =1500 mg/dL (=5.7 mmol/L and =17.0 mmol/L). Several exploratory outcomes will also be
Show less
Read more
Impact Snapshot
Event Time:
ACST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACST alerts
High impacting Acasti Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ACST
News
- Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. [Canadian Business Journal (Canada)]Canadian Business Journal
- Acasti Pharma changes name to Grace Therapeutics [Seeking Alpha]Seeking Alpha
- Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.GlobeNewswire
- Acasti Pharma Inc. (NASDAQ: ACST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Acasti Pharma Inc. (NASDAQ: ACST) had its price target raised by analysts at Craig Hallum from $6.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
ACST
Earnings
- 8/9/24 - Beat
ACST
Sec Filings
- 10/28/24 - Form 8-K
- 10/25/24 - Form 8-K
- 10/16/24 - Form EFFECT
- ACST's page on the SEC website